By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Genzyme Corporation 

500 Kendall Street

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-252-7500 Fax: 617-252-7600


About Genzyme

Genzyme is committed to discovering and delivering transformative therapies for patients with rare and special unmet medical needs, providing hope where there was none before.

Genzyme has pioneered the development and delivery of transformative therapies for over 30 years. Founded in 1981 in Boston, Massachusetts, Genzyme evolved from a tiny start-up with just a handful of employees to one of the world's leading biotech companies. Acquired by Sanofi in 2011, Genzyme now benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients.

Genzyme has long been known for our expertise in the class of rare genetic diseases known as lysosomal storage disorders (LSDs). LSDs remain the heart of our company today, but we have also expanded – through both in-house development and strategic acquisitions and partnerships – to other disease areas such as thyroid cancer and multiple sclerosis.

Learn more at

Follow our jobs on Twitter

Follow us on LinkedIn

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets, and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Key Statistics

Ownership: Subsidiary

Web Site: Sanofi Genzyme
Symbol: SNY



Medtronic  Cardiac Cell Therapy

Cambridge Antibody Technology (CAT)  Antibodies against TGF-ß

Dyax  Hereditary Angioedema


Company News
BARDA Awards $37.6 Million Contract To Sanofi Genzyme (SNY) To Supply Leukine (Sargramostim) For Potential Public Health Emergency 10/7/2016 11:27:58 AM
Editas Medicine (EDIT) Brings on New Execs From Sanofi Genzyme (SNY), Novartis AG (NVS), Baxalta (BXLT) and Bristol-Myers Squibb (BMY) 10/5/2016 7:19:35 AM
FDA Set to Decide on Two Likely Blockbuster Drugs By Sanofi Genzyme (SNY) 9/26/2016 6:19:16 AM
Treatment Effects Maintained Over Six Years In Patients With Relapsing Remitting Multiple Sclerosis Who Received Sanofi Genzyme (SNY)’s Lemtrada (Alemtuzumab) In Clinical Trials 9/16/2016 11:11:46 AM
Results From 1,000-Patient, Global Real-World Patient-Reported Outcomes Study Of Sanofi Genzyme (SNY)’s Aubagio (Teriflunomide) In Patients With Relapsing Multiple Sclerosis Demonstrate High Levels Of Treatment Satisfaction 9/15/2016 10:40:19 AM
More Than 35 Presentations Of New Investigational Data From Sanofi Genzyme (SNY)’s Multiple Sclerosis Franchise To Be Featured At ECTRIMS 9/7/2016 1:42:58 PM
Sanofi Genzyme (SNY) Release: Alberta Includes LEMTRADA (Alemtuzumab) On Provincial Drug Program For Eligible Patients 9/1/2016 9:42:32 AM
Sanofi Genzyme (SNY) Release: New Brunswick Includes LEMTRADA (Alemtuzumab) On Provincial Drug Program For Eligible Patients 8/25/2016 8:26:20 AM
Sanofi Genzyme (SNY) Release: Ontario Adds LEMTRADA (Alemtuzumab) To The Exceptional Access Program For Eligible Patients 7/21/2016 6:37:13 AM
Sanofi Genzyme (SNY) Begins Pivotal Phase II/III Trial Of Olipudase Alfa For Adult Patients With Acid Sphingomyelinase Deficiency 7/6/2016 10:31:20 AM